Real-world effectiveness and safety of teduglutide in adult and pediatric patients with short bowel syndrome in Argentina

Table 5 Serious treatment-emergent adverse events, n (%)

	Adults (n = 21)		Pediatric (n = 24)
	All TEAE	Severe TEAE	All TEAE	Severe TEAE
Infections and infestations
Catheter site infection	0 (0)	0 (0)	1 (4.1)	0 (0)
Device related infection	0 (0)	0 (0)	2 (8.3)	1 (4.1)
Influenza	0 (0)	0 (0)	1 (4.1)	0 (0)
Rhinovirus infection	0 (0)	0 (0)	1 (4.1)	0 (0)
Vascular device infection	0 (0)	0 (0)	1 (4.1)	0 (0)
General disorders and administration site conditions
Vascular device occlusion	0 (0)	0 (0)	1 (4.1)	0 (0)
Metabolism and nutrition disorders
Hypolabuminaemia	0 (0)	0 (0)	1 (4.1)	0 (0)
Lactic acidosis	0 (0)	0 (0)	1 (4.1)	0 (0)
Injury, poisoning and procedural complications
Stoma complications1	1 (4.7)	0 (0)	2 (8.3)	1 (4.1)
Hepatobiliary disorders
Cholestasis	0 (0)	0 (0)	1 (4.1)	0 (0)
Hyperbilirubinemia	0 (0)	0 (0)	1 (4.1)	0 (0)
Blood and lymphatic system disorders
Anaemia	0 (0)	0 (0)	1 (4.1)	0 (0)
Investigations
Liver function test abnormal	0 (0)	0 (0)	1 (4.1)	0 (0)
Nervous system disorders
Seizure	0 (0)	0 (0)	1 (4.1)	0 (0)

¹One in adults and one in pediatric considered adverse event of special interest (AESI); considered AESI.

All serious treatment-emergent adverse event in the overall study population (n = 45). TEAE: Treatment-emergent adverse event.